electroCore to Announce Fourth Quarter and Year Ended December 31, 2022 Financial Results on Wednesday, March 8
01 mars 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial...
electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa
21 févr. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with...
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
16 févr. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and...
electroCore Completes Sale of New Jersey Tax Benefits
15 févr. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of...
electroCore Announces Reverse Stock Split
14 févr. 2023 10h30 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse...
electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update
17 janv. 2023 08h00 HE
|
electroCore, Inc.
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022Revenue growth of approximately 57% over full-year 2021Launched two new...
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
20 déc. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called...
electroCore Announces Issuance of Two New U.S. Patents
07 déc. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...
gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
18 nov. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has...
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
14 nov. 2022 16h05 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...